Investigational New Drugs

Article	Citations
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials	43
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma	38
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway	38
A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizot	34
Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells	34
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors	32
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study	31
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma	30
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA	30
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations	27
Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials	27
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation	27
A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment	26
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model	26
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors	25
Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects	24
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer	23
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study	23
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study	21
Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer	20
Challenging and new opportunities for prodrug technology	20
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label	19
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification	19
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs	18
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors	17

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates	17
IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis	15
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer	15
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells	15
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis	15
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation	14
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study	14
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors	14
Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells	14
The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis	14
Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate	14
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study	14
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers	13
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation	13
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells	13
The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells	13
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial	13
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases	13
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines	13
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer	12
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study	12
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects	12
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines	12
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4	12
Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer	12
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines	12
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors	12
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes	11
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy	10
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate c	10
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery	10
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients	10
Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment	10
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma	10
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma	9
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors	9
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group	9
Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication	9
Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data	9
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study	9
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma	9
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with n	9
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer	9
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma	8
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells	8
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy	8
A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor	8
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer	8
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin	8
Immunotherapy in thymic epithelial tumors: an attractive dilemma	8

Clinical features, treatment, and outcomes of nivolumab induced psoriasis	8
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-	7
Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma	7
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer	7
Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis	7
Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy	7
Correction to: Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma	7
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non‐small cell lung cancer	7
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer	7
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents	7
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma	7
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase	7
SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC	7
3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new	7
The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients	7
Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma	7
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis	7
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer	7
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients	6
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia	6
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macro	6
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors	6
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors	6
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma	6
Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors	6
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation	6
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer	6
Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines	6
An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer	6
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy	6
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells	6
Effect of PAWI-2 on pancreatic cancer stem cell tumors	6
Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study	6
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients	6
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA	6
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report	6
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia	6
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer	5
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system	5
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia	5
Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine	5
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors	5
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity	5
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort	5
Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects	5
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study	5
Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer	5
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630	5
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome	5
Prospective role of liquid biopsy for early screening in laryngeal cancer	5
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors	5
The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model	5
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer	5
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma	5
DGG-300273, a novel WNT/β-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells	5
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib	4
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models	4
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease	4
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study	4
Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study	4
Clinical features, diagnosis, and treatment of pembrolizumab induced autoimmune encephalitis	4
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer	4
Practical consideration for successful sequential tumor biopsies in first-in-human trials	4
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells	4
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study	4
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report	4
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma	4
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else	4
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)	4
Brigatinib pharmacokinetics in patients with chronic hepatic impairment	4
AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB)	4
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy	4
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer	4
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma	4
A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors	4
Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR	4
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors	4
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study	4
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors	4
Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer	4

Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays	4
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer	4
Network pharmacology of triptolide in cancer cells: implications for transcription factor binding	4
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors	4
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib	4
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice	4
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models	4
Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial	4
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition	4
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States	4
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healt	4
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells	4
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis	4
177Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model	4
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis	3
A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Her	3
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport	3
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel	3
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells	3
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma	3
Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics	3
Manganese improves anti-PD-L1 immunotherapy via eliciting type I interferon signaling in melanoma	3
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome	3
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells	3
Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects	3
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer	3
Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia	3
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer	3
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis	3
Modulation of peritumoral fibroblasts with a membrane-tethered tissue inhibitor of metalloproteinase (TIMP) for the elimination of cancer cells	3
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors	3
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrosp	3
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer	3
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review	3
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles	3
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma	3
Mesenchymal stem cells: a trojan horse to treat glioblastoma	3
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study	3
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial	3
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma	3
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper	3
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study	3
Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia	2
Vebreltinib: a promising milestone in targeted therapy for METex14-mutant NSCLC	2
The biological function of IGF2BPs and their role in tumorigenesis	2
Dual PTCH2 mutation [Ser391*, Leu104Pro]: unveiling a potential new genetic susceptibility factor for glioma development	2
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma	2
Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma	2
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis	2
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors	2
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells	2
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors	2
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?	2
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo	2
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma	2
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China	2
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis	2
Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis	2
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer	2
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA	2
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies	2
A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target	2
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma	2
Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]	2
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis	2
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors	2
In vitro selection of DNA aptamers against human osteosarcoma	2
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer	2
Correction to: Clinical research progress of fruquintinib in the treatment of malignant tumors	2
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects	2
The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines	2
IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer	2
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies	2
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Pro	2
Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the trea	2
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial	2
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors	2
Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients	2
Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis	2
Evolving or immutable - phase I solid tumor trials in the era of precision oncology	2
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study	2
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II	2
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis	2
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations	2